Fostamatinib disodium (R935788)

DRUG4 trials

Sponsors

Rigel Pharmaceuticals, AstraZeneca

Conditions

Rheumatoid ArthritisSystemic Lupus Erythematosus

Phase 2

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)

CompletedNCT00665626

Rigel PharmaceuticalsRheumatoid Arthritis

Start: 2008-05-31End: 2009-06-30Updated: 2017-05-01

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

CompletedNCT00665925

Rigel PharmaceuticalsRheumatoid Arthritis

Start: 2008-05-31End: 2009-06-30Updated: 2016-09-16

Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus

WithdrawnNCT00752999

Rigel PharmaceuticalsSystemic Lupus Erythematosus

Start: 2008-11-30End: 2010-03-31Updated: 2012-04-30

Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

TerminatedNCT00805467

AstraZenecaRheumatoid Arthritis

Start: 2008-08-31End: 2013-08-31Updated: 2014-06-25

Related Papers

Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.

2013-02-0137 citations

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

2010-09-22282 citations